Shots:

• The collaboration combines expertise- resources and technology from both parties to develop and manufacture variant vaccines against SARS-CoV-2 variants. CureVac is expected to supply 50M doses of variant vaccines to the UK- following the regulatory approval
• The VTF and the CureVac will deploy mRNA platform to assess multiple SARS-CoV-2 variants and are expected to generate vaccine candidates against selected ones
• Additionally- CureVac will transfer its technology to enable the manufacturing of clinical & commercial quantities of any vaccines that result from the collaboration- as well as manufacturing of CureVac’s existing vaccine against SARS-CoV-2 (CVnCoV)- currently in P-III study

 ­ Ref: CureVAc | Image: CureVAc